# Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

> **NCT00458042** · PHASE4 · TERMINATED · sponsor: **United Therapeutics** · enrollment: 10 (estimated)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** treprostinil sodium

## Key facts

- **NCT ID:** NCT00458042
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 10 (ESTIMATED)
- **Why stopped:** Low Enrollment
- **Last updated:** 2007-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458042, "Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00458042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*